Search Results - "Mita, Sachiko"

Inhibition of Bile Acid Transport across Na+/Taurocholate Cotransporting Polypeptide (SLC10A1) and Bile Salt Export Pump (ABCB 11)-Coexpressing LLC-PK1 Cells by Cholestasis-Inducing Drugs by MITA, Sachiko, SUZUKI, Hiroshi, AKITA, Hidetaka, HAYASHI, Hisamitsu, ONUKI, Reiko, HOFMANN, Alan F, SUGIYAMA, Yuichi

“…Vectorial transport of bile acids across hepatocytes is a major driving force for bile flow, and bile acid retention in the liver causes hepatotoxicity. The…”
Get full text

Vectorial transport of bile salts across MDCK cells expressing both rat Na+-taurocholate cotransporting polypeptide and rat bile salt export pump by Mita, Sachiko, Suzuki, Hiroshi, Akita, Hidetaka, Stieger, Bruno, Meier, Peter J, Hofmann, Alan F, Sugiyama, Yuichi

“…Bile salts are predominantly taken up by hepatocytes via the basolateral Na(+)-taurocholate cotransporting polypeptide (NTCP/SLC10A1) and secreted into the…”
Get more information

Population Pharmacokinetic and Exposure–Safety Analyses of Ibrutinib for the Treatment of Chronic Graft‐Versus‐Host Disease by Ogawa, Tetsuro, Mita, Sachiko, Atluri, Harisha, Iwaki, Yuki

“…The population pharmacokinetic (PK) and exposure–response (E–R) analyses for the safety of ibrutinib for the treatment of chronic graft‐versus‐host disease…”
Get full text

MO29-6 Safety and tolerability of lazertinib and in combination with amivantamab in advanced EGFR-mutated Japanese NSCLC by Goto, Koichi, Hida, Toyoaki, Funami, Nobuyuki, Iwasawa, Ryota, Mita, Sachiko, Yamashita, Aimi, Imanaka, Keiichiro, Kitani, Sumiko, Ohe, Yuichiro

Get full text

Surveys/Research Exploring Japanese Phase I Studies in Global Drug Development: Are They Necessary Prior to Joining Global Clinical Trials? by Hirano, Masaru, Yamada, Masanori, Tanaka, Toshiaki, Koue, Toshiko, Saito, Tomohisa, Higashimori, Mitsuo, Ochiai, Hisao, Yamamoto, Junichi, Yaguchi, Saori, Mita, Sachiko, Hara, Katsutoshi

Get full text

Effect of Renal Impairment on the Pharmacokinetics of Pradigastat, a Novel Diacylglycerol Acyltransferase1 (DGAT1) Inhibitor by Mita, Sachiko, Meyers, Dan, Pal, Parasar, Lin, TsuHan, Majumdar, Tapan, Rebello, Sam, Sunkara, Gangadhar, Chen, Jin

“…Background and Objective Pradigastat, a diacylglycerol acyltransferase1 inhibitor, is being developed for the treatment of familial chylomicronemia syndrome…”
Get full text

Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes by YAMAGUCHI, Masayuki, SAJI, Takami, MITA, Sachiko, KULMATYCKI, Kenneth, HE, Yan-Ling, FURIHATA, Kenichi, SEKIGUCHI, Kaneo

“…To assess the extent of pharmacokinetic and pharmacodynamic interaction between vildagliptin, a potent and selective inhibitor of dipeptidyl peptidase IV…”
Get full text

Vectorial transport of unconjugated and conjugated bile salts by monolayers of LLC-PK1 cells doubly transfected with human NTCP and BSEP or with rat Ntcp and Bsep by Mita, Sachiko, Suzuki, Hiroshi, Akita, Hidetaka, Hayashi, Hisamitsu, Onuki, Reiko, Hofmann, Alan F, Sugiyama, Yuichi

“…Na(+)-taurocholate-cotransporting peptide (NTCP)/SLC10A1 and bile salt export pump (BSEP)/ABCB11 synergistically play an important role in the transport of…”
Get more information

Bioequivalence and food effect assessment for vildagliptin/metformin fixed-dose combination tablets relative to free combination of vildagliptin and metformin in Japanese healthy subjects by Mita, Sachiko, Chitnis, Shripad D, Kulmatycki, Kenneth, Salunke, Atish, He, Yan-Ling, Zhou, Wei, Suzuki, Hikoe

“…To assess the bioequivalence of vildagliptin/metformin fixeddose combination (FDC) tablets (50/250 mg and 50/500 mg) to free combinations of vildagliptin and…”
Get full text

Population pharmacokinetic modeling and noncompartmental analysis demonstrated bioequivalence between metformin component of metformin/vildagliptin fixed-dose combination products and metformin immediate-release tablet sourced from various countries by Chitnis, Shripad D., Han, Yi, Yamaguchi, Masayuki, Mita, Sachiko, Zhao, Rong, Sunkara, Gangadhar, Kulmatycki, Kenneth

“…Metformin is the first‐line pharmacotherapy choice for treating type‐2 diabetes mellitus, alone or in combination with other antidiabetic drugs. During the…”
Get full text